Hilltop National Bank Invests $33,000 in Liquidia Co. (NASDAQ:LQDA)

Hilltop National Bank purchased a new stake in shares of Liquidia Co. (NASDAQ:LQDA) during the second quarter, Holdings Channel.com reports. The firm purchased 2,752 shares of the company’s stock, valued at approximately $33,000.

Several other hedge funds have also made changes to their positions in the company. Trexquant Investment LP acquired a new stake in shares of Liquidia in the fourth quarter worth $770,000. LB Partners LLC purchased a new position in Liquidia during the 4th quarter valued at about $3,404,000. Vestal Point Capital LP acquired a new position in shares of Liquidia in the 4th quarter valued at about $12,331,000. Kynam Capital Management LP lifted its position in shares of Liquidia by 34.9% in the fourth quarter. Kynam Capital Management LP now owns 2,698,324 shares of the company’s stock worth $32,461,000 after purchasing an additional 698,324 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its holdings in shares of Liquidia by 119.4% during the first quarter. BNP Paribas Financial Markets now owns 230,248 shares of the company’s stock worth $3,396,000 after purchasing an additional 125,315 shares during the period. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on LQDA. HC Wainwright reiterated a “buy” rating and issued a $32.00 price objective on shares of Liquidia in a research note on Wednesday, July 10th. Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 price target on shares of Liquidia in a research note on Thursday, July 18th. Finally, Oppenheimer initiated coverage on Liquidia in a report on Tuesday, June 25th. They set a “market perform” rating for the company. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $21.60.

Insider Buying and Selling

In other Liquidia news, CFO Michael Kaseta sold 3,906 shares of the stock in a transaction that occurred on Friday, July 12th. The stock was sold at an average price of $12.53, for a total transaction of $48,942.18. Following the transaction, the chief financial officer now owns 312,389 shares in the company, valued at $3,914,234.17. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, CEO Roger Jeffs sold 8,053 shares of the stock in a transaction that occurred on Friday, July 12th. The stock was sold at an average price of $12.53, for a total value of $100,904.09. Following the completion of the sale, the chief executive officer now directly owns 818,932 shares of the company’s stock, valued at $10,261,217.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Michael Kaseta sold 3,906 shares of the firm’s stock in a transaction that occurred on Friday, July 12th. The stock was sold at an average price of $12.53, for a total value of $48,942.18. Following the completion of the sale, the chief financial officer now owns 312,389 shares of the company’s stock, valued at approximately $3,914,234.17. The disclosure for this sale can be found here. In the last ninety days, insiders sold 21,437 shares of company stock worth $268,549. 31.60% of the stock is currently owned by insiders.

Liquidia Stock Performance

Shares of Liquidia stock traded down $0.38 during midday trading on Wednesday, reaching $10.68. 1,296,122 shares of the company’s stock traded hands, compared to its average volume of 876,776. The company has a market cap of $816.06 million, a price-to-earnings ratio of -6.85 and a beta of 0.32. Liquidia Co. has a 52 week low of $5.71 and a 52 week high of $16.99. The company’s 50 day simple moving average is $12.34 and its 200 day simple moving average is $13.32.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings results on Monday, May 13th. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.22). The company had revenue of $2.97 million during the quarter, compared to analyst estimates of $4.31 million. Liquidia had a negative return on equity of 177.83% and a negative net margin of 674.42%. As a group, equities research analysts predict that Liquidia Co. will post -1.39 earnings per share for the current year.

Liquidia Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).